



Article

# Prokaryotic Expression and Functional Verification of Antimicrobial Peptide LR<sub>CG</sub>

Xiang Liu <sup>1,†</sup> , Yining Ding <sup>1,†</sup>, Yuhan Shen <sup>1</sup>, Sizhuo Liu <sup>1</sup>, Yuehua Liu <sup>2</sup>, Yuting Wang <sup>1</sup>, Shikun Wang <sup>1,2</sup>, Claudio Orlando Gualerzi <sup>3</sup>, Attilio Fabbretti <sup>3</sup>, Lili Guan <sup>1</sup>, Lingcong Kong <sup>1</sup>, Haipeng Zhang <sup>1</sup>, Hongxia Ma <sup>1,\*</sup> and Chengguang He <sup>1,\*</sup>

<sup>1</sup> Engineering Research Center, The Chinese Ministry of Education for Bioreactor and Pharmaceutical Development, College of Life Sciences, Jilin Agricultural University, Changchun 130118, China; liuxiang\_0915@163.com (X.L.); wangyuting990501@163.com (Y.W.)

<sup>2</sup> Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China

<sup>3</sup> School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy

\* Correspondence: hongxia0731001@163.com (H.M.); hechengguang@jlu.edu.cn (C.H.)

† These authors contributed equally to this work.

**Abstract:** The antimicrobial peptide LR<sub>CG</sub> (LLRLLRRGGRRLLRLL-NH<sub>2</sub>) was designed and chemically synthesized in a study conducted by Jia et al. Gram-negative bacteria were found to be sensitive to LR<sub>CG</sub> and exhibited a high therapeutic index. Genetic engineering methods were used to create the prokaryotic fusion expression vector pQE-GFP-LR<sub>CG</sub>, and the resulting corresponding fusion protein GFP-LR<sub>CG</sub> was subsequently expressed and purified. The precursor GFP was then removed by TEV proteolysis, and pure LR<sub>CG</sub> was obtained after another round of purification and endotoxin removal. The prokaryotic-expressed antimicrobial peptide LR<sub>CG</sub> displays a broad-spectrum antibacterial effect on Gram-negative bacteria, and its minimum inhibitory activity (MIC) against *Escherichia coli* can reach 2 µg/mL. Compared to the chemically synthesized LR<sub>CG</sub>, the prokaryotic-expressed LR<sub>CG</sub> exhibits similar temperature, pH, salt ion, serum stability, and cell selectivity. Furthermore, prokaryotic-expressed LR<sub>CG</sub> showed excellent therapeutic effects in both the infection model of cell selectivity and no embryotoxicity in a *Galleria mellonella* infection model. The mechanism by which LR<sub>CG</sub> causes bacterial death was found to be the disruption of the Gram-negative cell membrane.

**Keywords:** antimicrobial peptides; prokaryotic expression; antibacterial mechanism



**Citation:** Liu, X.; Ding, Y.; Shen, Y.; Liu, S.; Liu, Y.; Wang, Y.; Wang, S.; Gualerzi, C.O.; Fabbretti, A.; Guan, L.; et al. Prokaryotic Expression and Functional Verification of Antimicrobial Peptide LR<sub>CG</sub>. *Int. J. Mol. Sci.* **2024**, *25*, 7072. <https://doi.org/10.3390/ijms25137072>

Academic Editor: Rustam I. Aminov

Received: 23 May 2024

Revised: 17 June 2024

Accepted: 24 June 2024

Published: 27 June 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Untreatable multidrug-resistant infections are becoming more common, causing an alarming number of deaths [1]. To address this issue, scientists are exploring alternative methods to develop drugs that can target cell components or mechanisms that are less prone to mutation, resulting in resistance [2,3]. Among the new antimicrobial substances being developed, antimicrobial peptides (AMPs) show great potential as a new source of effective antimicrobial activity [4–6].

AMPs, also known as host defense peptides, are the oldest innate immune defense factors [7] and play a crucial role in the natural immune system of the host [8]. Recent studies have revealed that AMPs use unique antimicrobial mechanisms that differ from those of the antibiotics commonly used in clinical infections [9–11]. There are a variety of AMPs that bind to microbes through low-affinity targets, a condition that greatly reduces the chance of generating antimicrobial resistance [12]. AMPs are categorized according to their effect on the bacterial membrane or membrane proteins [13–17]. Under stress conditions, the occurrence of mutations in these areas is reduced, thus decreasing the chance of developing resistance [17–22]. These AMPs are the original innate immune defense factors, also known as host defense peptides [21]. They are crucial to the host's innate immune response [22]. Research has shown that AMPs have a unique mechanism of

action against microorganisms, unlike the current antibiotics used to treat infections. They have multiple low-affinity targets with microorganisms, and because of its fast degradation rate, it will not produce drug residues, which reduces antibiotic resistance. In light of these properties, AMPs have the potential to be used as drugs to treat infections caused by microorganisms [23–25].

It has been shown that the designed AMP LR<sub>GG</sub> (LLRLLRRGRRLLRLL-NH<sub>2</sub>), which tends to form an  $\alpha$ -helical structure in membrane-mimetic environments [26], exhibits effective antimicrobial activity against Gram-negative bacteria when used in combination with ciprofloxacin, colistin, and other antibiotics. This combination has been found to reverse the ciprofloxacin-resistant phenotype of *Pasteurella multocida* and increase 512-fold the antibacterial activity of ciprofloxacin against this bacterium (unpublished data from our laboratory).

The chemically synthesized peptide LR<sub>GG</sub> has been found to damage the bacterial outer membrane by targeting lipopolysaccharide (LPS) and disrupting the Fe<sup>3+</sup> transport system involving the inner membrane permease protein FecD, thereby significantly improving the efficacy of ciprofloxacin in the treatment of animals infected with multidrug-resistant *Escherichia coli* and *Pasteurella multocida*. The LR<sub>GG</sub> peptide can also trigger membrane potential hyperpolarization and intracellular accumulation of reactive oxygen species (ROS) in pathogenic bacteria, leading to synergistic bactericidal effects. However, neither the isolation nor the chemical synthesis of AMPs is a good choice for clinical application. In fact, the isolation of natural AMPs from hosts is impractical due to their low concentration and complicated purification procedure, while the use of synthetic AMPs is limited by the high costs of their chemical synthesis.


Currently, the most effective strategy to produce AMPs on a large scale is biological expression [27,28], with the expression in *Escherichia coli* being the most commonly used method in light of its low production costs, short incubation period, and ease of control [29,30]. However, the production of AMPs composed of only ten to a dozen amino acids in prokaryotic expression systems can be challenging [31]. An additional drawback is that AMPs produced within prokaryotes can result in cell inhibition. To avoid this problem and increase the AMPs production rate, a larger protein tag, such as green fluorescence protein (GFP), can be fused to AMPs [32,33]. GFP is commonly used as a protein label and can also be used for easily observable expression detection [34,35].

In this study, the GFP was tandemly fused with the N' terminus of AMP LR<sub>GG</sub> and cloned and inserted into the pQE80 *Escherichia coli* expression vector to act as a precursor protein, and a target site for the TEV protease was inserted between the GFP fusion protein-encoding gene and the LR<sub>GG</sub>, thus enabling the fusion label to be easily removed during purification. pQE80 is a vector plasmid used for protein expression, hosted by *Escherichia coli*, having the prokaryotic resistance of Kanamycin and being a promoter of T5, suitable for expressing short peptides. The cleavage site affects only one amino acid of the main protein chain with minimal impact on the protein properties [36]. In this study, the effects of AMP LR<sub>GG</sub> expression on the cell membrane and DNA of Gram-negative bacteria were also investigated through tests of the permeability of the inner and outer membranes, cell membrane potential, and electrophoretic mobility shift assay (EMSA).

## 2. Results

### 2.1. Construction of the pQE-GFP-LR<sub>GG</sub> Expression Vector


Agarose gel electrophoresis analysis of the linearized pQE80-KAN vector, GFP gene, and TEV site LR<sub>GG</sub> gene sequences confirmed that their fragment lengths were 5329 bp, 719 bp, and 72 bp, respectively (Figure 1A). PCR identification of the transformed competent clones using the primers pQE30+ and pQE30– revealed the expected band size of 961 bp for the GFP + LR<sub>GG</sub> + TEV restriction sites, as shown in Figure 1B. These results validated the successful construction of the prokaryotic expression vector pQE-GFP-LR<sub>GG</sub>.



**Figure 1.** Construction of PQE-GFP-LR<sub>GG</sub> expression vector. (A) lane M: Trans5K DNA Marker; lane 1: Linearized pQE80-KAN vector; lane 2: gfp gene; lane 3: TEV site—LR<sub>GG</sub> fragmen. (B) lane M: Trans2K DNA Marker; lane 1: GFP + TEV sites restriction + LR<sub>GG</sub>.

### 2.2. Expression and Purification of the Fusion Protein GFP-LR<sub>GG</sub>

The expression and purification of all the samples were verified through SDS-PAGE, and the corresponding results are shown in Figure 2. Notably, the target band measuring 31 kDa was found in lane 3, indicating that GFP-LR<sub>GG</sub>, the intended protein, could be eluted with 300 mM imidazole. Additionally, the concentration of the purified target protein was quantified to be 4.7 mg/L using a BCA kit.




**Figure 2.** SDS-PAGE gel electrophoresis result of fusion protein GFP-LR<sub>GG</sub> purification. Lane 1: Before purification; lane 2: Flow through; M: Molecular weight standard; lanes 3–7: elution of 300 mM Imidazole.

### 2.3. Cutting of the Fusion Protein and Purification of the Antibacterial Peptide LR<sub>GG</sub>

The recombinant TEV enzyme cleaved the GFP, which was subsequently purified using a Ni-NTA column and analyzed via Tricine-SDS-PAGE electrophoresis. In Figure 3, the results show that the strip in lane 2 is slightly lower than the pre-cut strip in lane 1 and has the same height as the strip passing through the liquid. This indicates that the fusion label was successfully removed, leaving behind a band with a minimal molecular weight consistent with the chemical synthesis of LR<sub>GG</sub> in lane 4. To summarize, the recombinant

TEV enzyme cleaved the GFP, and the prokaryotic-expressed antimicrobial peptide LR<sub>GG</sub> was successfully purified through multiple purification methods. The concentration of the protein, as measured by the BCA reagent kit, was an average of 1.4 mg/L.



**Figure 3.** Tricine-SDS-PAGE gel electrophoresis result of LR<sub>GG</sub>, with cleavage by TEV enzyme. M: Protein marker (3.3–20.1 kD, Solarbio life sciences, Beijing, China). 1: Before cutting; 2: After TEV enzyme cutting; 3: Purified LR<sub>GG</sub> of TEV enzyme cutting; 4: Chemically synthesized of LR<sub>GG</sub>.

#### 2.4. Determination of the Bacteriostatic Activity and Kinetics Curve of Fusion-Expressed Antimicrobial Peptide LR<sub>GG</sub>

This study employed the microdilution method to assess the minimum inhibitory concentrations of both the expressed and synthetic LR<sub>GG</sub> peptides. Table 1 presents the results, which reveal that LR<sub>GG</sub> antimicrobial peptides demonstrate exceptional broad-spectrum antibacterial activity against Gram-negative bacteria, surpassing their efficacy against Gram-positive bacteria. Notably, the MIC of prokaryotic-expressed and chemically synthesized antimicrobial peptides were found to be similar, while the fusion protein showed no antibacterial activity.

**Table 1.** MICs of the antimicrobial peptide LR<sub>GG</sub> against bacteria (μM).

Test Strains	MICs (μg/mL)		
	Chem. Syn. LR <sub>GG</sub>	Expressed LR <sub>GG</sub>	Fusion Protein GFP-LR <sub>GG</sub>
Gram-negative			
<i>Escherichia coli</i> ATCC25922	2	2	>512
<i>S. pullorum</i> NCTC5776	4	4	>512
<i>K. pneumoniae</i> ATCC46117	8	16	>512
<i>P.aeruginosa</i> ATCC27853	8	8	>512
<i>S.flexneri</i> CMCC51572	8	8	>512
Gram-positive bacteria			
<i>Staphylococcus aureus</i> ATCC25923	32	32	>512
<i>S. aureus</i> ATCC29213	16	16	>512
<i>Enterococcus faecalis</i> ATCC29212	32	32	>512
MRSA	256	128	>512

### 2.5. Environmental Sensitivity of Fusion Expressed Peptide LR<sub>GG</sub>

Temperature and pH stability: Based on the data presented in Table 2, both the expressed and chemically synthesized LR<sub>GG</sub> demonstrated remarkable temperature and pH stability. Specifically, the MIC value of these peptides increased by four-fold at 100 °C and by two-fold and four-fold at pH 10. These findings demonstrate that LR<sub>GG</sub> exhibits excellent stability under conditions that are typically considered harsh, highlighting its potential as a promising candidate for various applications.

**Table 2.** MIC value of the antimicrobial peptide LR<sub>GG</sub> against *Escherichia coli* ATCC25922 at different temperatures and pH values.

AMPs	Control (pH 7)	Temperature			pH			
		0 °C	37 °C	100 °C	pH 4	pH 6	pH 8	pH 10
Chem. syn. LR <sub>GG</sub>	2	2	2	8	2	2	4	4
Expressed LR <sub>GG</sub>	2	2	4	8	2	4	2	16
Melittin	1	1	1	2	2	1	1	2

According to the data presented in Table 3, the MIC values of melittin was substantially greater than the MIC values of protease-treated melittin. This finding highlights the importance of proteases in reducing the stability of melittin. Furthermore, it has been reported that the peptide LR<sub>GG</sub> is unstable in the presence of proteases.

**Table 3.** MIC values of the antibacterial peptide LR<sub>GG</sub> against *Escherichia coli* ATCC25922 under the action of different enzymes.

Peptide	Control	Proteinase (1 mg/mL)			
		Trypsin	Pepsin	Papain	Protease K
Chem. syn. LR <sub>GG</sub>	2	>128	>128	>64	>64
Expressed LR <sub>GG</sub>	4	>128	>128	>64	>64
Melittin	2	4	4	2	4

Salt Ion Stability: Given the abundance of salt ions present in physiological environments, it is important to assess the MIC values of the antimicrobial peptide LR<sub>GG</sub> when expressed versus when chemically synthesized in various salt ion environments. As demonstrated in Table 4, compared with those in the control, the MICs of the prokaryotic-expressed and chemically synthesized peptides in a 150 mM NaCl solution decreased by only two- to four-fold. Therefore, it can be concluded that both the expressed and chemically synthesized peptide LR<sub>GG</sub> possess commendable salt ion stability.

**Table 4.** MIC values of the antimicrobial peptide LR<sub>GG</sub> against *Escherichia coli* ATCC25922 under different salt ion environments.

Peptide	Control	Physical Salt Concentration				
		CaCl <sub>2</sub>	NaCl	KCl	NH <sub>4</sub> Cl	MgCl <sub>2</sub>
Chem. Syn. LR <sub>GG</sub>	2	4	8	2	2	4
Expressed LR <sub>GG</sub>	4	4	8	8	4	8
Melittin	2	4	4	2	2	2

Concentration of Salt Ion Solution: 2.5 mM CaCl<sub>2</sub>, 150 mM NaCl, 4.5 mM KCl, 6 mM NH<sub>4</sub>Cl, 1 mM MgCl<sub>2</sub>, 8 mM ZnCl<sub>2</sub>.

Serum stability: The MIC for peptide LR<sub>GG</sub>, both expressed and chemically synthesized, were assessed against *Escherichia coli* ATCC25922 at various serum concentrations. The results are presented in Table 5. Notably, the MIC for LR<sub>GG</sub> fluctuates at serum concentrations of 20% to 50%, ultimately increasing four-fold. Conversely, the MIC values for


melittin plateaued at 128 at a 10% concentration, demonstrating minimal antibacterial activity. These findings suggest that the serum environment has little impact on the antibacterial effectiveness of LR<sub>GG</sub>, regardless of its method of synthesis.

**Table 5.** MIC values of the antimicrobial peptide LR<sub>GG</sub> against *Escherichia coli* ATCC25922 at different serum concentrations.


Peptide	Control	Serum				
		5%	10%	20%	40%	50%
Chem. syn. LR <sub>GG</sub>	2	2	2	8	16	16
Expressed LR <sub>GG</sub>	2	2	4	32	32	32
Melittin	2	32	128	128	128	128

### 2.6. Cytotoxicity and Hemolytic Activity of Antimicrobial Peptide LR<sub>GG</sub>

The effectiveness of the expressed and synthetic peptides LR<sub>GG</sub> against RAW264.7 and Vero cell was evaluated, as demonstrated in Figure 4). At MIC values of 1–64, the chemically synthesized antimicrobial peptide exhibited a slightly higher cell survival rate compared to the prokaryotic-expressed antimicrobial peptide. However, both the expressed and synthetic peptides showed over 80% cell survival rate against RAW264.7 and Vero cells, in contrast to the control melittin. Compared with that of the melittin control, the hemolytic activity of chemically synthesized LR<sub>GG</sub> was less than 10% compared to the melittin control at MIC values of 1–64 µg/mL, as shown in Figure 5. The hemolytic activity of the expressed LR<sub>GG</sub> was slightly more than 10% at 64 µg/mL, but the hemolytic index was less than 10% at the lowest inhibitory concentration. When the MIC value is 128 µg/mL, the hemolytic activity of the expressed LR<sub>GG</sub> is slightly higher than 20%, which may have slight toxicity [37]. The comparable cytotoxicity and hemolytic activity of LR<sub>GG</sub>-expressed and chemically synthesized LR<sub>GG</sub> demonstrated that the antimicrobial peptide LR<sub>GG</sub> has excellent cell selectivity at minimum inhibitory concentrations.




**Figure 4.** Cytotoxicity of the expressed peptide LR<sub>GG</sub> and the synthetic peptide LR<sub>GG</sub> to RAW264.7 (A) and Vero (B) cells. Note: \*\*\*  $p < 0.001$  indicates a very significant difference, \*\*  $p < 0.01$  indicates a very significant difference.



**Figure 5.** Hemolytic activity of the expressed peptide LR<sub>GG</sub> and the synthetic peptide LR<sub>GG</sub> on sheep red blood cells.

### 2.7. Embryotoxicity of the Antimicrobial Peptide LR<sub>GG</sub> in Zebrafish

The results of embryotoxicity tests conducted on zebrafish that were exposed to LR<sub>GG</sub> expression and chemically synthesized antimicrobial peptide are shown in Figure 6. The hearts of zebrafish that were exposed to LR<sub>GG</sub> expression (a positive control) with high concentrations of sodium dehydroacetate (200 μg/mL) showed significant hemorrhage and severe bending of the fish. Conversely, exposure to expressed LR<sub>GG</sub> and chemically synthesized LR<sub>GG</sub> at a concentration of 1 × MIC, comparable to that of the negative control, did not change the morphology of the zebrafish. These results indicate that neither the expressed nor the chemically synthesized antimicrobial peptide LR<sub>GG</sub> had any toxic effects on zebrafish.




**Figure 6.** Embryonic safety of the expressed peptide LR<sub>GG</sub> and the synthetic peptide LR<sub>GG</sub> in zebrafish. (A) Negative control containing culture medium; (B) Containing 1 × Expression peptide LR<sub>GG</sub> at MIC concentration; (C) Containing 200 μg/mL sodium dehydroacetate; (D) Containing 1 × MIC of the Chemical Synthesis Peptide LR<sub>GG</sub>.

### 2.8. Inner and Outer Membrane Permeability Tests

As depicted in Figure 7A, the permeability of the inner membrane of the recombinant antimicrobial peptide LR<sub>GG</sub> increased within 0–50 min, and further increased with increasing dose and prolonged exposure. These results indicate that the prokaryotic-expressed antimicrobial peptide LR<sub>GG</sub> effectively ruptures the inner membrane of bacterial cells at the minimum inhibitory concentration. Additionally, as illustrated in Figure 7B, the peptide was able to penetrate the outer membrane of cells in a concentration-dependent manner at concentrations ranging from 1 to 32 μM. Notably, when the concentration of LR<sub>GG</sub> exceeded


8  $\mu\text{M}$ , the outer membrane permeability was observed to be more than 80%. These findings suggest that the prokaryotic-expressed antimicrobial peptide LR<sub>GG</sub> can effectively destroy the bacterial cell outer membrane at the minimum inhibitory concentration.



**Figure 7.** Pairs E. expressing peptide LR<sub>GG</sub> Inner (A) and Outer (B) Membrane Permeability of *Escherichia coli* ATCC25922. Note: \*\*\*  $p < 0.01$ , there is a very significant difference, \*\*  $p < 0.01$ , there is a very significant difference, \*  $p < 0.05$ , there is a significant difference.

### 2.9. Effect of the Antimicrobial Peptide LR<sub>GG</sub> on the Bacterial Plasma Membrane Potential


According to Figure 8, when the diSC3-5 fluorescent dye enters the cell membrane, it can form non-luminescent polymers [38]. However, if the cell membrane is destroyed, the previously entered diSC3-5 will flow out and be detected through its fluorescence value. Over time and concentration within 0–1500 s at 1–8 MIC, the fluorescence value of prokaryotic-expressed antimicrobial peptide LR<sub>GG</sub> gradually increased, indicating its impact on the bacterial cytoplasmic membrane potential. This further confirmed that the expressed peptide LR<sub>GG</sub> is capable of destroying the bacterial cell membrane.



**Figure 8.** Effect of the antimicrobial peptide LR<sub>GG</sub> on the plasma membrane potential of *Escherichia coli* ATCC25922. Note: \*\*\*  $p < 0.01$ , there is a very significant difference.

### 2.10. DNA Gel Retardation Assay

The determination of LR<sub>GG</sub>'s binding to DNA can be determined through a DNA gel retardation assay, as depicted in Figure 9A. Through this assay, it was discovered that LR<sub>GG</sub> effectively binds to the genomic DNA of *Escherichia coli* ATCC 25922 and impedes its migration toward the positive pole when the peptide concentration reaches 256  $\mu\text{M}$ . In addition, as shown in Figure 9B, LR<sub>GG</sub> effectively blocked plasmid DNA migration toward the positive pole only when the peptide concentration reached 128  $\mu\text{M}$ .



**Figure 9.** EMSA of genomic DNA (A) and plasmid DNA (B). (A) The effect of LR<sub>CG</sub> on the genomic DNA of *Escherichia coli* ATCC 25922 EMSA test. M: DL10000 DNA Marker; 1–10: Gradually increasing concentrations of LR<sub>CG</sub> peptide (1–512  $\mu$ M); 11: Positive control; 12: Negative control. In addition, all 1–12 with *Escherichia coli* ATCC 25922 genome (300 ng/ $\mu$ L). (B) Effects of different concentrations of LR<sub>CG</sub> on the pkk3535 plasmid EMSA test. M: DL10000 DNA Marker; 1–10: Gradually increasing concentrations of LR<sub>CG</sub> peptide (1–512  $\mu$ M); 11: positive control; 12: Negative control. In addition, all 1–12 with pKK3535 plasmid (300 ng/ $\mu$ L).

### 3. Discussion

Natural AMPs are present at low concentrations in host organisms and are challenging to isolate due to complicated purification procedures. The high cost of chemical synthesis also limits the use of synthetic AMPs, making neither isolation nor chemical synthesis of AMPs good choices for clinical application. Therefore, this study aimed to produce and test the antimicrobial properties of a fully designed AMP that effectively fights against Gram-negative bacteria, which is the peptide LR<sub>CG</sub>.

The mode of expression of AMPs and protein tag fusion plays a crucial role in bacterial expression systems. This affects their subsequent purification. In a study by Chen Xin et al., four fusion tags (TrxA, SUMO, protein internal peptides, and GST) were fused with Mycelin and expressed in *Escherichia coli* for purification and antimicrobial activity assays [39]. Ali et al. fused GFP with the cell insect toxin Cit1a for expression in silkworms. This finding is consistent with the use of GFP and antimicrobial peptide fusion for expression. This approach effectively prevents the bactericidal effects of antimicrobial peptides on the host bacterium and allows further purification of the antimicrobial peptide [40]. The 6X His tag added in this study can be used to purify antimicrobial peptides. The construction method used in this study combines the fusion tag GFP with the TEV restriction enzyme and adds the antimicrobial peptide LR<sub>CG</sub>, which has been reported in previous research. In this study, the expression vector pQE-GFP-LR<sub>CG</sub> was constructed, and the GFP-LR<sub>CG</sub> fusion protein was produced by prokaryotic expression. After chromatographic purification and TEV protease cleavage, the purity-expressed LR<sub>CG</sub> was prepared.

Furthermore, the effects of the MIC and different environmental conditions on the antimicrobial peptide LR<sub>CG</sub> were examined. The findings demonstrate that LR<sub>CG</sub> exhibits excellent stability under conditions that are typically considered harsh, highlighting its potential as a promising candidate for various applications. However, the results showed that the stability of the peptide LR<sub>CG</sub> toward proteases could be improved. This is particularly important because the body contains multiple proteases that can break down proteins. The peptide segment of LR<sub>CG</sub> is short, consisting of only 16 amino acids, making it highly susceptible to proteolytic degradation. Consequently, the MIC decreased significantly, while the antibacterial activity decreased after protease treatment. Researchers have suggested that modifying the chemical structure of AMPs can enhance the stability of their polypeptides, preventing them from being degraded by proteins [41]. Additionally, the use of liposome-coated AMPs for delivery can also maintain their stability and

reduce their toxicity [42]. This approach has potential clinical benefits for the application of antimicrobial peptides.

In vitro experiments were conducted to measure the cytotoxicity and hemolytic activity of chemically synthesized and expressed LR<sub>GG</sub>. The results of safety assessment experiments at the cellular level revealed that LR<sub>GG</sub> exhibited no hemolytic activity, and no cytotoxicity was detected for either chemically synthesized or expressed LR<sub>GG</sub> at MIC values of 1–64. Therefore, further research was conducted to determine the toxicity of LR<sub>GG</sub> to zebrafish embryos. The results showed that the expression of LR<sub>GG</sub> and chemical synthesis of LR<sub>GG</sub> at a concentration of 1 × MIC, comparable to the negative control, did not change the morphology of the zebrafish. These results indicate that neither the expressed nor chemically synthesized antimicrobial peptide LR<sub>GG</sub> had any toxic effects on zebrafish.

The structure of AMPs is crucial to their biological function. The antimicrobial peptide LR<sub>GG</sub> examined in this study has an amino acid sequence of (LLRLLRRGGRRLLLLRLL-NH<sub>2</sub>) and is composed of an α-helix structure [26]. With arginine as a positively charged amino acid and leucine as a hydrophobic amino acid, it has a tremendous membrane-breaking structure. The positive charge of this antimicrobial peptide and the negative control on the bacterial membrane increase membrane permeability due to electrostatic interactions. This leads to the release of the antimicrobial peptide LR<sub>GG</sub> into the cell plasma membrane, eventually causing lysis of the plasma membrane and leading to the death of microbial pathogens. In addition, bacteria can be inhibited by disrupting bacterial cell membranes. In another study, LR<sub>GG</sub> was shown to be even more effective when used in combination with ciprofloxacin, colistin, and other antibiotics. LR<sub>GG</sub> damages the outer membrane of pathogenic bacteria by targeting LPS and disrupting the ability of the Fe<sup>3+</sup> transport system to permease the FecD protein in the inner membrane (unpublished data). In this study, the antimicrobial peptide LR<sub>GG</sub> only bonded to DNA at high concentrations, not at the MIC. We suspect that this could be because the DNA double-strand itself is negatively charged, and the antimicrobial peptide is positively charged. As the concentration of antimicrobial peptide increases, it will naturally bind to DNA. Therefore, the exact antibacterial mechanism of the antimicrobial peptide LR<sub>GG</sub> after rupture at the lowest inhibitory concentration requires further study.

#### 4. Materials and Methods

##### 4.1. Strains and Plasmids

The chemically synthesized AMP LR<sub>GG</sub> (LLRLLRRGGRRLLLLRLL-NH<sub>2</sub>) is a fully designed peptide, purchased from Sangong Co., Ltd. Shanghai, China.

##### 4.2. Acquisition of Target Genes

- (1) To target the GFP gene, we designed GFP-F and GFP-R primers (as show in Table 6) from the plasmid pTZ18U-GFP previously constructed in the laboratory. PrimeStar Max DNA Polymerase was used to amplify the GFP gene via PCR, with the plasmid pTZ18U-GFP as (show in Table 7) serving as the template.
- (2) To target the gene sequence of the antimicrobial peptide LR<sub>GG</sub>, the primers LR<sub>GG</sub>-F1 and LR<sub>GG</sub>-R1 were designed. The seamless cloning method were followed to construct the plasmids, as shown in Figure 10.

**Table 6.** Primers used in this study.


Gene	Primer	Sequence (5'-3')
linear pQE Vector	pQE-VT-F	GTAAAAGCTTAATTAGCTGAGCTTGGACTCC
	pQE-VT-R	CATATCTCTAGAGGATCCGTGATGGTG
GFP	GFP-F	CTAGAGATATGCGTAAAGGAGAAGAACTTTTCACTG
	GFP-R	AAGATTCTCATACTGTATAGTTCATCCATGCCATGTGTAATCCC
LR <sub>GG</sub>	LR <sub>GG</sub> -F1	CTTACAGCAGACGCAGCAGACGACGGCCGCCACGACGCAG
	LR <sub>GG</sub> -R1	GAGAATCTTTIATTTTCAGGGCCTGCTGCGTCTGCTGCGTCGTGGCGGC

Table 6. Cont.

Gene	Primer	Sequence (5'-3')
TEV cleavage site + LR <sub>GG</sub>	TEV-LR <sub>GG</sub> -F2	GAGAATCTTTATTTTCAGGGCCTGCTGCGTCTGCTGCGTCGTGGCGGC
	TEV-LR <sub>GG</sub> -R2	TTACAGCAGACGCAGCAGACGACGGCCGCCACGACGCAG
validation primers	M13-F	AGGGTTTTCCAGTCACG
	M13-R	GAGCGGATAACAATTTTCACAC
	pQE30+	GTGAGCGGATAACAATTTTCAC
	pQE30-	CTGAACAAATCCAGATGGAG

Table 7. Strains and plasmids.

Strains	Source
<i>Escherichia coli</i> stellar component cell	Takara
Transetta component cell	Takara
<i>Escherichia coli</i> ATCC 25922	Preserved by the Pharmacology and Toxicology Laboratory of Jilin Agricultural University
<i>S. pullorum</i> NCTC5776	
<i>K. Pneumoniae</i> CMCC 46117	
<i>Paeruginosa</i> ATCC27853	
<i>S.flexneri</i> CMCC51572	
<i>S.aureus</i> ATCC 25923	
<i>S. faecalis</i> ATCC 29212	
Plasmids	
pQE-80-Kan	Qiagen
pMD-18T	Takara
pTZ18U-GFP	Takara

Figure 10. pQE-GFP-LR<sub>GG</sub> plasmid map.

#### 4.3. Construction of pQE-GFP-LR<sub>GG</sub> Expression Vector

To construct the pQE-GFP-LR<sub>GG</sub> vector, three gene fragments were amplified.

- (1) The *gfp* gene was amplified by PCR reaction using the primers GFP-F and GFP-R, and the pTZ18U-GFP plasmid served as the template.
- (2) To synthesize the Tev site and LR<sub>GG</sub> sequence, two oligonucleotides (TEV-LR<sub>GG</sub>-F2 and TEV-LR<sub>GG</sub>-R2) were mixed at a 1:1 ratio in a PCR reaction buffer. The mixture was denatured at 95 °C and annealed by reducing the temperature by one degree per minute from 95 °C to 25 °C within 70 min. This process yielded a double-stranded LR<sub>GG</sub> DNA sequence containing the TEV target site.
- (3) The linearized pQE80 vector was amplified by PCR using the pQE-VT-F and pQE-VT-R primers and the pQE80-KAN plasmid as a template.

The LR<sub>GG</sub> expression vector was created using the seamless cloning technique. In this process, the *gfp* gene fragment was placed in front of the fusion protein. A TEV cleavage site was added between the *gfp* and the LR<sub>GG</sub> fragment. These fragments were then placed behind the T5 promoter, and the His tag sequence was located in the pQE80-KAN vector. These genes were fused and connected through approximately 15 bp of complementary gene fragments. To carry out seamless cloning, a 20 µL reaction mixture consisting of 100 ng of *gfp* fragment, 50 ng of Tev site-LR<sub>GG</sub> fragment, 100 ng of linearized pQE80-KAN vector, and 4 µL of seamless enzyme was prepared. The reaction mixture was incubated for 15 min at 50 °C and then placed on ice. The construct was then transformed into Stellar competent cells (Takara). Stellar competent cells have high transformation efficiency and are especially suitable for the preparation of high copy plasmids. Following the manufacturer's protocol, the cells were plated onto LB plates containing 50 µg/mL kanamycin and incubated overnight. Positive clones were screened using the PCR reaction of test primers pQE30+ and pQE30– and DNA sequencing. The positive clone was then grown, and the expression vector was extracted and transformed into Transgene (DE3) competent cells.

#### 4.4. Expression and Purification of Fusion Protein GFP-LR<sub>GG</sub>

The transformed clone, verified by sequencing, was placed in 20 mL of LB medium containing 50 µg/mL kanamycin, centrifuged at 180 rpm, and incubated overnight at 37 °C. When the optical density reached 0.5, protein expression was induced by 0.2 mM Isopropyl β-D-Thiogalactoside (IPTG). After an additional 4 h of incubation, the cells were collected by centrifugation at 8000 rpm at 4 °C and the cell pellet was stored at –80 °C.

To obtain the GFP-LR<sub>GG</sub> fusion protein, the *Escherichia coli* cells were lysed using a sonicator at 18 W for six rounds of 30 s bursts in Buffer A (20 mM Tris-HCl pH 7.4, 5% glycerol, 500 mM NaCl). The samples were supplemented immediately before use with 6 mM β-Mercaptoethanol, 0.1 mM Benzamidine, and 0.1 mM Phenylmethanesulfonyl fluoride (PMSF). The lysate was passed through a Ni-NTA 6FF column. Proteins with no affinity for the column were eluted with Buffer A containing 50 mM imidazole, whereas the fusion protein was eluted with Buffer A containing 300 mM imidazole. The fractions containing the fusion protein detected by SDS-PAGE electrophoresis were pooled and dialyzed against buffer A to eliminate imidazole, and the fusion protein was concentrated, analyzed with a Bicinchoninic Acid Assay (BCA) test kit, and stored at –80 °C.

#### 4.5. Cleavage of the Fusion Protein and Purification of the Antimicrobial Peptide LR<sub>GG</sub>

The TEV protease was used to cleave the GFP-LR<sub>GG</sub> fusion protein [43] in a reaction mixture consisting of 100 µL of 10× TEV Buffer supplemented with 50 µL of recombinant TEV protease (1 mg/mL from Beyotime Co., Ltd., Shanghai, China) and 40 µg of the fusion protein GFP-LR<sub>GG</sub> (1 mg/mL). After 16 h of incubation at 16 °C, the 6× His-tag remained upstream of the GFP, while no His-tag remained linked to LR<sub>GG</sub>. Using a Ni-NTA affinity column, the two products of the digestion of the fusion protein were separated by passage through an affinity column that was able to retain the 6× His-GFP while allowing the LR<sub>GG</sub> peptide to pass through upon elution with 20 mM Tris-HCl (pH 8.0) buffer containing 200 mM of glycerol, 500 mM sodium chloride, and 300 mM imidazole. The effluent containing GFP-LR<sub>GG</sub> was dialyzed against buffer A containing 50% glycerol. After checking its purity by Tricine-SDS-PAGE, the protein was stored at –80 °C.

#### 4.6. Determination of the Antibacterial Activity of Fusion Expressed Antimicrobial Peptide LR<sub>GG</sub>

The minimal inhibitory concentrations against various bacteria displayed by peptides expressed in prokaryotes and chemically synthesized were determined by the broth microdilution method. Two replicates were set up by placing 100 µL of the two antimicrobial peptides (approximately 1024 µg/mL each) in the first rows of the 96-well plates, followed by serial two-fold dilutions to achieve final peptide concentrations ranging from 512 to 1 µg/mL. The strains kept at –80 °C were reactivated, plated, and incubated overnight at

37 °C. Single colonies were picked, inoculated into 5 mL of MH medium, and cultured until they reached  $OD_{600} = 0.5$ . The bacterial suspensions were then diluted to  $1 \times 10^5$  CFU/mL, and 50  $\mu$ L was added to wells 1–11. Then, 50  $\mu$ L and 100  $\mu$ L of deionized water were added to wells 11 and 12, respectively, to provide a positive and a negative control. The concentration of peptide present in the first non-turbid well in which bacterial growth was inhibited was taken as the minimal inhibitory concentration (MIC). This experiment was repeated three times.

#### 4.7. Determination of the Bactericidal Kinetic Curve of Fusion Expressed Antimicrobial Peptide LR<sub>GG</sub>

To determine the bactericidal kinetic curve of in vivo-expressed and synthetic peptide, the bacterial suspension was mixed with two peptides to obtain a final peptide concentration corresponding to  $4 \times$  MIC. The plate was then shaken at 37 °C and 180 rpm, taking 50  $\mu$ L aliquots of the bacterial suspension every 20 min and diluting them two-fold with sterile PBS buffer before they were spread evenly on LB-containing solid media and incubated overnight at 37 °C (12–16 h). The number of colonies on each plate was counted, and the number of colonies at 30–300 was taken as the control group. The group not exposed to the antimicrobial peptide was used as a control. The experiment was repeated three times, and the bactericidal kinetic curve was plotted.

#### 4.8. Environmental Sensitivity of Fusion Expressed Antimicrobial Peptide LR<sub>GG</sub>

The efficacy of the chemically synthesized and in vivo-expressed LR<sub>GG</sub> peptide were tested for their efficacy against *Escherichia coli* ATCC 25922 under various conditions, such as heat and different pH conditions, before determining their MIC in triplicate. In one case, the peptides were placed in ice-cold water at 0 °C and heated to 37 °C and 100 °C for 30 min each, and their efficacy was compared to that of an untreated control group. This process was repeated three times. In another case, the peptides were exposed for one hour to pH values of 4, 6, 8, and 10, and their activity was compared to that of an untreated control group. In another set of experiments, the peptides were mixed and incubated with 1 mg/mL of four different proteases. After inactivation of the enzymes, the peptides were tested for their efficacy against *Escherichia coli* ATCC 25922. The peptides were also tested after mixing with various salt solutions and concentrations of fetal bovine serum at concentrations ranging from 5% to 50%. In all cases, the MIC were determined in triplicate using untreated antimicrobial peptides as controls.

#### 4.9. Cytotoxicity Assay of the Antimicrobial Peptide LR<sub>GG</sub>

The cytotoxicity of both in vivo-expressed and synthesized LR<sub>GG</sub> peptides was determined using the Cell Counting Kit-8 (CCK-8) colorimetric assay on RAW 264.7 and Vero cells. To ensure consistency, before the addition to the cell culture plate the in vivo-expressed peptide was diluted with synthetic peptide LR<sub>GG</sub> using deionized water to achieve a 1–128  $\mu$ g/mL concentration gradient. The peptides were then incubated with the cells for 16 h at 37 °C in a 5% CO<sub>2</sub> incubator, with two sets of replicates for each assay. After incubation, 10  $\mu$ L of 10% CCK solution was added to each well and incubated for 4 h at 37 °C in a 5% CO<sub>2</sub> incubator. The OD<sub>450</sub> was measured, and the process was repeated three times for accuracy.

#### 4.10. Hemolytic Activity Assay of the Antimicrobial Peptide LR<sub>GG</sub>

To obtain a suspension containing 2% red blood cells, 15 mL of sheep blood was collected in a tube containing 0.2% sodium heparin anticoagulant and centrifuged at 1000 rpm for 10 min. After discarding the supernatant, the red blood cell pellet was collected, washed twice with sterile phosphate buffered saline (PBS), and resuspended in PBS. The expressed peptide was then diluted with deionized water containing synthetic LR<sub>GG</sub> to achieve a final concentration with the same gradient as the MIC value (1–128  $\mu$ g/mL). After the erythrocyte suspension was incubated with the antimicrobial peptide LR<sub>GG</sub> for one hour at 37 °C,

the mixture from each well of the 96-well plate was aspirated and centrifuged at  $1000 \times g$  for 10 min. The absorbance of the supernatant was then measured at 570 nm, with three repeats and averaging. Finally, the hemolytic index was calculated as follows: Hemolytic index (%) =  $(\text{O.D. peptide} - \text{O.D. PBS}) / (\text{O.D. TritonX} - 100 - \text{O.D. PBS}) \times 100\%$ .

#### 4.11. Embryotoxicity of the Antimicrobial Peptide LR<sub>GG</sub> in Zebrafish

In this experiment, AB-strain zebrafish embryos were introduced to express and synthesize the antimicrobial peptide LR<sub>GG</sub> at a concentration of  $1 \times \text{MIC}$ . A sodium dehydroacetate solution of 200  $\mu\text{g}/\text{mL}$  served as the positive control, while the negative control group contained only culture medium. The embryos were cultured in a constant temperature incubator at 28 °C for approximately 2–3 days, and their morphology after fertilization was observed using a light microscope.

#### 4.12. Inner and Outer Membrane Permeability Tests

To measure the effectiveness of the antimicrobial peptide LR<sub>GG</sub>, bacterial suspensions were prepared with 1.5 mM O-Nitrophenyl  $\beta$ -D-galactopyranoside (ONPG) buffer at an ABS O.D. of 600 = 0.5. The experiment was conducted by adding varying concentrations of the expressed antimicrobial peptide LR<sub>GG</sub> (1/2 – 4 MIC) to the same volume of *Escherichia coli* ATCC25922 bacterial solution, successively plated in 96-well plates. PBS was added to the control group. The absorbance was then measured at ABS O.D. = 420 nm using a microplate reader at 5-minute intervals for 50 min.

To determine the permeability of the bacterial membrane, N-Phenyl-1-naphthylamine (NPN), a fluorescent dye that cannot enter a bacterial membrane with an intact structure, was used [44]. First, black 96-well plates were used, and the same volume of bacterial suspension and different concentrations of expressed antimicrobial peptides were added. PBS was added to the control group, and 1 mM NPN fluorescent dye was added to reach a final concentration of 10  $\mu\text{M}$ . The plates were then incubated in the dark at room temperature for 30 min, and their O.D. values were measured with a fluorescence microplate reader using an excitation wavelength of 350 nm and an emission wavelength of 420 nm.

The formula used to calculate the outer membrane permeability was

$$\text{NPN absorption (\%)} = (F_{\text{obs}} - F_0) / (F_{100} - F_0) \times 100\%,$$

where  $F_{\text{obs}}$  is the fluorescence value measured in the presence of antimicrobial peptides and  $F_0$  is the fluorescence value of the negative control.  $F_{100}$  is the fluorescence value of the positive control. The experiment was conducted in triplicate for each group.

#### 4.13. Effect of the Antimicrobial Peptide LR<sub>GG</sub> on the Bacterial Plasma Membrane Potential

To determine whether the expressed antimicrobial peptide LR<sub>GG</sub> can break bacterial cytoplasmic membranes, diSC<sub>3-5</sub> was used as a fluorescent dye to monitor changes in membrane potential. A bacterial suspension was prepared and adjusted to an ABS O.D. of 600 = 0.5. Next, the same volume of bacterial suspension and varying concentrations of expressed antimicrobial peptide LR<sub>GG</sub> (1–8 MIC) were added to black 96-well plates. A control group was established using PBS, and diSC<sub>3-5</sub> dye was added to a final concentration of 0.4  $\mu\text{M}$  and incubated at room temperature in the dark for one hour. Changes in absorbance values between 0 and 1500 s were measured using a fluorescence microplate reader at excitation (622 nm) and emission (670 nm) wavelengths.

#### 4.14. DNA Gel Retardation Assay

The *Escherichia coli* ATCC 25922 genome was extracted, and its concentration was determined to be OD260/OD280 = 1.8~2.0. Genomic DNA (400 ng) and the expressed antimicrobial peptide LR<sub>GG</sub> at final concentrations ranging from 1~512  $\mu\text{M}$  were incubated at 37 °C for 1 h and verified by 1% agarose gel electrophoresis. The experimental data obtained in this study were statistically analyzed using GraphPad Prism 8.0 software. The data are presented as the mean and standard deviations.

The genome of *Escherichia coli* ATCC 25922 was isolated, and its concentration was determined to be OD<sub>260</sub>/OD<sub>280</sub> = 1.8~2.0. Genomic DNA (400 ng) and the expressed LR<sub>GG</sub> were incubated at 37 °C for one hour at final concentrations in the range of 1~512 µM. The results were verified via 1% agarose gel electrophoresis. To analyze the data obtained in this study, GraphPad Prism 8.0 software was used for statistical analysis. The data are presented as the mean and standard deviations.

## 5. Conclusions

This study has uncovered valuable insights into the antimicrobial functional peptide LR<sub>GG</sub>, which is expressed through the prokaryotic expression vector pQE-GFP-LR<sub>GG</sub>. This study demonstrated that the fusion protein of AMP LR<sub>GG</sub> has a wide range of antibacterial effects on Gram-negative bacteria. Additionally, the peptide has shown remarkable stability under various environmental conditions, such as temperature, pH, salt ion, and serum conditions. Moreover, this peptide has been proven in tested animal models to be safe at its minimal inhibition concentration, which is encouraging for prospective antibacterial treatments. Under concentration-dependent conditions, LR<sub>GG</sub> expressed in prokaryotes can cause damage to the inner and outer membranes of Gram-negative bacteria, as well as affect the cytoplasmic membrane potential, leading to their death. This groundbreaking development in the realm of antibacterial treatments holds great potential.

**Author Contributions:** C.H. and H.M. conceived and designed the research. Y.S., Y.W., S.L., Y.L., S.W., H.Z., and L.K. conducted the experiments. C.O.G. and A.F. contributed new reagents or analytical tools. L.K. and L.G. analyzed the data. X.L. and Y.D. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by the Jilin Scientific and Technological Development Program (Grant number: 20230402037GH) and the Open Research Fund of the Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education (Grant number: KF202101), which was provided by He Yu-Hua of Jilin Agricultural Science and Technology University, Animal Science and Technology College, Jilin, China.

**Institutional Review Board Statement:** The animal study protocol was approved by the Institutional Animal Care and Use Committee of Jilin Agricultural University (no. 20220416004, 17 April 2022) and carried out in accordance with the approved guidelines.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The datasets supporting the conclusions of this article will be made available by the authors without undue reservation.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Bruce, J.; Oyedemi, B.; Parsons, N.; Harrison, F. Phase 1 safety trial of a natural product cocktail with antibacterial activity in human volunteers. *Sci. Rep.* **2022**, *12*, 19656. [[CrossRef](#)] [[PubMed](#)]
2. Tsang, J. Bacterial plasmid addiction systems and their implications for antibiotic drug development. *Postdoc J.* **2017**, *5*, 3–9. [[CrossRef](#)] [[PubMed](#)]
3. Xu, L.; Wang, W.; Xu, W. Effects of tetracycline antibiotics in chicken manure on soil microbes and antibiotic resistance genes (ARGs). *Environ. Geochem. Health* **2021**, *44*, 273–284. [[CrossRef](#)] [[PubMed](#)]
4. Wiman, E.; Zattarin, E.; Aili, D.; Bengtsson, T.; Selegård, R.; Khalaf, H. Development of novel broad-spectrum antimicrobial lipopeptides derived from plantaricin NC8 β. *Sci. Rep.* **2023**, *13*, 4104. [[CrossRef](#)] [[PubMed](#)]
5. Topalova, Y.; Belouhova, M.; Velkova, L.; Dolashki, A.; Zheleva, N.; Daskalova, E.; Kaynarov, D.; Voelter, W.; Dolashka, P. Effect and Mechanisms of Antibacterial Peptide Fraction from Mucus of *C. aspersum* against *Escherichia coli* NBIMCC 8785. *Biomedicines* **2022**, *10*, 672. [[CrossRef](#)] [[PubMed](#)]
6. Tallet, L.; Frisch, E.; Bornerie, M.; Medemblik, C.; Frisch, B.; Lavalle, P.; Guichard, G.; Douat, C.; Kichler, A. Design of Oligourethane-Based Foldamers with Antibacterial and Antifungal Activities. *Molecules* **2022**, *27*, 1749. [[CrossRef](#)] [[PubMed](#)]
7. Mardirossian, M.; Rubini, M.; Adamo, M.F.A.; Scocchi, M.; Saviano, M.; Tossi, A.; Gennaro, R.; Caporale, A. Natural and Synthetic Halogenated Amino Acids—Structural and Bioactive Features in Antimicrobial Peptides and Peptidomimetics. *Molecules* **2021**, *26*, 7401. [[CrossRef](#)] [[PubMed](#)]

8. Hanson, M.A.; Lemaitre, B.; Unckless, R.L. Dynamic Evolution of Antimicrobial Peptides Underscores Trade-Offs Between Immunity and Ecological Fitness. *Front. Immunol.* **2019**, *10*, 2620. [[CrossRef](#)]
9. Lin, Y.; Jiang, Y.; Zhao, Z.; Lu, Y.; Xi, X.; Ma, C.; Chen, X.; Zhou, M.; Chen, T.; Shaw, C.; et al. Discovery of a Novel Antimicrobial Peptide, Temporin-PKE, from the Skin Secretion of *Pelophylax kl. esculentus*, and Evaluation of Its Structure-Activity Relationships. *Biomolecules* **2022**, *12*, 759. [[CrossRef](#)]
10. Tomb, R.M.; Maclean, M.; Coia, J.E.; MacGregor, S.J.; Anderson, J.G. Assessment of the potential for resistance to antimicrobial violet-blue light in *Staphylococcus aureus*. *Antimicrob. Resist. Infect. Control.* **2017**, *6*, 100. [[CrossRef](#)]
11. Czechowicz, P.; Neubauer, D.; Nowicka, J.; Kamysz, W.; Gościński, G. Antifungal Activity of Linear and Disulfide-Cyclized Ultrashort Cationic Lipopeptides Alone and in Combination with Fluconazole against Vulvovaginal *Candida* spp. *Pharmaceutics* **2021**, *13*, 1589. [[CrossRef](#)]
12. Popa, C.; Shi, X.; Ruiz, T.; Ferrer, P.; Coca, M. Biotechnological Production of the Cell Penetrating Antifungal PAF102 Peptide in *Pichia pastoris*. *Front. Microbiol.* **2019**, *10*, 1472. [[CrossRef](#)] [[PubMed](#)]
13. Vinutha, A.S.; Rajasekaran, R. Insight on the mechanism of hexameric Pseudin-4 against bacterial membrane-mimetic environment. *J. Comput. Mol. Des.* **2023**, *37*, 419–434. [[CrossRef](#)]
14. Won, T.; Mohid, S.A.; Choi, J.; Kim, M.; Krishnamoorthy, J.; Biswas, I.; Bhunia, A.; Lee, D. The role of hydrophobic patches of de novo designed MSI-78 and VG16KRKP antimicrobial peptides on fragmenting model bilayer membranes. *Biophys. Chem.* **2023**, *296*, 106981. [[CrossRef](#)]
15. Kumar, P.; Kizhakkedathu, J.N.; Straus, S.K. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. *Biomolecules* **2018**, *8*, 4. [[CrossRef](#)] [[PubMed](#)]
16. Mandel, S.; Michaeli, J.; Nur, N.; Erbeti, I.; Zazoun, J.; Ferrari, L.; Felici, A.; Cohen-Kutner, M.; Bachnoff, N. OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria. *Sci. Rep.* **2021**, *11*, 6603. [[CrossRef](#)] [[PubMed](#)]
17. Mumtaz, S.; Behera, S.; Mukhopadhyay, K. Lipidated Short Analogue of  $\alpha$ -Melanocyte Stimulating Hormone Exerts Bactericidal Activity against the Stationary Phase of Methicillin-Resistant *Staphylococcus aureus* and Inhibits Biofilm Formation. *ACS Omega* **2020**, *5*, 28425–28440. [[CrossRef](#)]
18. Panevska, A.; Hodnik, V.; Skočaj, M.; Novak, M.; Modic, Š.; Pavlic, I.; Podržaj, S.; Zarić, M.; Resnik, N.; Maček, P.; et al. Pore-forming protein complexes from *Pleurotus* mushrooms kill western corn rootworm and Colorado potato beetle through targeting membrane ceramide phosphoethanolamine. *Sci. Rep.* **2019**, *9*, 5073. [[CrossRef](#)]
19. Panevska, A.; Čegovnik, N.; Fortuna, K.; Vukovič, A.; Grundner, M.; Modic, Š.; Bajc, G.; Skočaj, M.; Bohte, M.M.; Popošek, L.L.; et al. A single point mutation expands the applicability of ostreolysin A6 in biomedicine. *Sci. Rep.* **2023**, *13*, 2149. [[CrossRef](#)]
20. Rončević, T.; Puizina, J.; Tossi, A. Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era. *Int. J. Mol. Sci.* **2019**, *20*, 5713. [[CrossRef](#)]
21. Rima, M.; Rima, M.; Fajloun, Z.; Sabatier, J.M.; Bechinger, B.; Naas, T. Antimicrobial Peptides: A Potent Alternative to Antibiotics. *Antibiotics* **2021**, *10*, 1095. [[CrossRef](#)]
22. Lei, J.; Sun, L.C.; Huang, S.; Zhu, C.; Li, P.; He, J.; Mackey, V.; Coy, D.H.; He, Q.Y. The antimicrobial peptides and their potential clinical applications. *Am. J. Transl. Res.* **2019**, *11*, 3919–3931.
23. Mahlapuu, M.; Håkansson, J.; Ringstad, L.; Björn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. *Front. Cell. Infect. Microbiol.* **2016**, *6*, 194. [[CrossRef](#)] [[PubMed](#)]
24. Bin Hafeez, A.; Jiang, X.; Bergen, P.J.; Zhu, Y. Antimicrobial Peptides: An Update on Classifications and Databases. *Int. J. Mol. Sci.* **2021**, *22*, 11691. [[CrossRef](#)] [[PubMed](#)]
25. Upton, M.; Cotter, P.; Tagg, J. Antimicrobial Peptides as Therapeutic Agents. *Int. J. Microbiol.* **2012**, *2012*, 326503–326512. [[CrossRef](#)] [[PubMed](#)]
26. Jia, B.; Wang, Y.; Zhang, Y.; Wang, Z.; Wang, X.; Muhammad, I.; Kong, L.; Pei, Z.; Ma, H.; Jiang, X. High Cell Selectivity and Bactericidal Mechanism of Symmetric Peptides Centered on d-Pro-Gly Pairs. *Int. J. Mol. Sci.* **2020**, *21*, 1140. [[CrossRef](#)]
27. Sampaio de Oliveira, K.B.; Leite, M.L.; Rodrigues, G.R.; Duque, H.M.; da Costa, R.A.; Cunha, V.A.; de Loiola Costa, L.S.; da Cunha, N.B.; Franco, O.L.; Dias, S.C. Strategies for recombinant production of antimicrobial peptides with pharmacological potential. *Expert Rev. Clin. Pharmacol.* **2020**, *13*, 367–390. [[CrossRef](#)] [[PubMed](#)]
28. Mejía-Pitta, A.; Broset, E.; de la Fuente-Nunez, C. Probiotic engineering strategies for heterologous production of antimicrobial peptides. *Adv. Drug Deliv. Rev.* **2021**, *176*, 113863. [[CrossRef](#)] [[PubMed](#)]
29. Bartolo-Aguilar, Y.; Chávez-Cabrera, C.; Flores-Cotera, L.B.; Badillo-Corona, J.A.; Oliver-Salvador, C.; Marsch, R. The potential of cold-shock promoters for the expression of recombinant proteins in microbes and mammalian cells. *J. Genet. Eng. Biotechnol.* **2022**, *20*, 173. [[CrossRef](#)]
30. Ahmadi, Z.; Farajnia, S.; Farajzadeh, D.; Pouladi, N.; Pourvatan, N.; Karbalaieimahdi, M.; Shayegh, F.; Arya, M. Optimized Signal Peptide for Secretory Expression of Human Recombinant Somatotropin in *E. coli*. *Adv. Pharm. Bull.* **2022**, *13*, 339–349. [[CrossRef](#)]
31. Starr, C.G.; Wimley, W.C. Antimicrobial peptides are degraded by the cytosolic proteases of human erythrocytes. *Biochim. Biophys. Acta (BBA)-Biomembr.* **2017**, *1859*, 2319–2326. [[CrossRef](#)] [[PubMed](#)]
32. Deo, S.; Turton, K.L.; Kainth, T.; Kumar, A.; Wieden, H.J. Strategies for improving antimicrobial peptide production. *Biotechnol. Adv.* **2022**, *59*, 107968. [[CrossRef](#)] [[PubMed](#)]

33. Lee, T.H.; Carpenter, T.S.; D'haeseleer, P.; Savage, D.F.; Yung, M.C. Encapsulin carrier proteins for enhanced expression of antimicrobial peptides. *Biotechnol. Bioeng.* **2020**, *117*, 603–613. [[CrossRef](#)] [[PubMed](#)]
34. Chalfie, M. Green fluorescent protein as a marker for gene expression. *Trends Genet.* **1994**, *10*, 151. [[CrossRef](#)]
35. Müller, H.; Salzig, D.; Czermak, P. Considerations for the process development of insect-derived antimicrobial peptide production. *Biotechnol. Prog.* **2015**, *31*, 1–11. [[CrossRef](#)] [[PubMed](#)]
36. Blommel, P.G.; Fox, B.G. A combined approach to improving large-scale production of tobacco etch virus protease. *Protein Expr. Purif.* **2007**, *55*, 53–68. [[CrossRef](#)] [[PubMed](#)]
37. Blomstrand, E.; Posch, E.; Stepulane, A.; Rajasekharan, A.K.; Andersson, M. Antibacterial and Hemolytic Activity of Antimicrobial Hydrogels Utilizing Immobilized Antimicrobial Peptides. *Int. J. Mol. Sci.* **2024**, *25*, 4200. [[CrossRef](#)] [[PubMed](#)]
38. Chou, S.; Shao, C.; Wang, J.; Shan, A.; Xu, L.; Dong, N.; Li, Z. Short, multiple-stranded  $\beta$ -hairpin peptides have antimicrobial potency with high selectivity and salt resistance. *Acta Biomater.* **2016**, *30*, 78–93. [[CrossRef](#)]
39. Chen, X.; Shi, J.; Chen, R.; Wen, Y.; Shi, Y.; Zhu, Z.; Guo, S.; Li, L. Molecular chaperones (TrxA, SUMO, Intein, and GST) mediating expression, purification, and antimicrobial activity assays of plectasin in *Escherichia coli*. *Biotechnol. Appl. Biochem.* **2015**, *62*, 606–614. [[CrossRef](#)]
40. Ali, M.P.; Yoshimatsu, K.; Suzuki, T.; Kato, T.; Park, E.Y. Expression and purification of cyto-insectotoxin (Cit1a) using silkworm larvae targeting for an antimicrobial therapeutic agent. *Appl. Microbiol. Biotechnol.* **2014**, *98*, 6973–6982. [[CrossRef](#)]
41. Dale, B.A.; Fredericks, L.P. Antimicrobial peptides in the oral environment: Expression and function in health and disease. *Curr. Issues Mol. Biol.* **2005**, *7*, 119–133. [[PubMed](#)]
42. Brancatisano, F.L.; Maisetta, G.; Barsotti, F.; Esin, S.; Miceli, M.; Gabriele, M.; Giuca, M.R.; Campa, M.; Batoni, G. Reduced Human Beta Defensin 3 in Individuals with Periodontal Disease. *J. Dent. Res.* **2011**, *90*, 241–245. [[CrossRef](#)] [[PubMed](#)]
43. Raran-Kurussi, S.; Cherry, S.; Zhang, D.; Waugh, D.S. Removal of Affinity Tags with TEV Protease. *Methods Mol. Biol.* **2017**, *1586*, 221–230. [[PubMed](#)]
44. Dong, N.; Zhu, X.; Chou, S.; Shan, A.; Li, W.; Jiang, J. Antimicrobial potency and selectivity of simplified symmetric peptides. *Biomaterials* **2014**, *35*, 8028–8039. [[CrossRef](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.